Nombre del producto:6-chloro-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

IUPAC Name:6-chloro-3-(propan-2-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione

CAS:887581-47-7
Fórmula molecular:C7H9ClN2O2
Pureza:95%+
Número de catálogo:CM467305
Peso molecular:188.61

Unidad de embalaje Stock disponible Precio($) Cantidad
CM467305-100mg in stock ħǙǙ
CM467305-250mg in stock ƚƈij

Sólo para uso en I+D..

Formulario de consulta

   refresh    

Detalles del producto

Núm. De CAS :887581-47-7
Fórmula molecular:C7H9ClN2O2
Punto de fusión:-
Código de sonrisas:CC(C)N1C(=O)NC(Cl)=CC1=O
Densidad:
Número de catálogo:CM467305
Peso molecular:188.61
Punto de ebullición:
Nº Mdl:MFCD03001443
Almacenamiento:

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.

Column Infos

Mavacamten
CAMZYOS(Mavacamten) was recently approved in the European Union, following its approval in the U.S. and other markets worldwide, and is the first and only cardiac myosin inhibitor approved to treat adult patients with symptomatic obstructive hypertrophic cardiomyopathy(HCM).
Mavacamten is a first-in-class, targeted inhibitor of cardiac myosin, reduces the number of myosin-actin cross-bridges and thus decreases excessive contractility characteristic of HCM.